Drug Profile
Research programme: inhaled therapeutics - MannKind Corporation/Receptor Life Sciences
Latest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator MannKind Corporation; Receptor Life Sciences
- Class Anti-inflammatories; Muscle relaxants; Non-opioid analgesics; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammation; Neurological disorders; Pain
Most Recent Events
- 17 Sep 2018 No recent reports on development identified for early research in Inflammation in USA (Inhalation)
- 17 Sep 2018 No recent reports on development identified for early research in Neurological disorders in USA (Inhalation)
- 17 Sep 2018 No recent reports on development identified for early research in Pain in USA (Inhalation)